Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

A convergence of epidemiological and clinical features has prompted a precipitous rise in
the prevalence of atrial fibrillation (AF) in the expanding population of adults with congenital …

Adult congenital heart disease (ACHD) is a constantly expanding population with
challenging issues. Initial medical and surgical treatments are seldom curative, and the …

Abstract Objective Adult Fontan patients are at increased risk for thrombosis and
thromboembolic complications leading to increased morbidity and mortality. Most are …

Blood coagulation is a physiological process whose main task is prevention of blood loss
from injured vessels. This process consists of a series of zymogens proteolytic activation …

Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have several advantages over
VKAs that render them an attractive option for adults with congenital heart disease (CHD) …

Abstract Background Vitamin K antagonists (VKAs) are frequently prescribed to patients with
congenital heart disease (CHD) for atrial arrhythmias or Fontan palliation, but there is a …

Abstract Purpose Direct oral anticoagulants (DOACs) are not recommended in adult Fontan
patients (Level of Evidence C). We hypothesized that DOACs are comparable to warfarin …

Background Coagulation abnormality is associated with a high incidence of intracardiac
thrombus (ICT) and systemic thromboembolism in Fontan patients. The biomarker for …

Abstract The initial “Frontiers in Fontan Failure” conference in 2015 in Atlanta, GA, provided
an opportunity for experts in the field of pediatric cardiology and adult congenital heart …